Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Evaluate Hologic's (HOLX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
3 Nov 2025 (In 3 months) Date | | 1.1 Cons. EPS | - EPS |
3 Nov 2025 (In 3 months) Date | | 1.07 Cons. EPS | - EPS |
30 Jul 2025 Date | | 1.05 Cons. EPS | - EPS |
28 Jul 2025 Date | | 1.05 Cons. EPS | 1.08 EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
3 Nov 2025 (In 3 months) Date | | 1.1 Cons. EPS | - EPS |
3 Nov 2025 (In 3 months) Date | | 1.07 Cons. EPS | - EPS |
30 Jul 2025 Date | | 1.05 Cons. EPS | - EPS |
28 Jul 2025 Date | | 1.05 Cons. EPS | 1.08 EPS |
30 Apr 2025 Date | | - Cons. EPS | - EPS |
Medical - Instruments & Supplies Industry | Healthcare Sector | Stephen P. MacMillan CEO | NASDAQ (NGS) Exchange | 436440101 Cusip |
US Country | 7,063 Employees | - Last Dividend | 3 Apr 2008 Last Split | 21 Jun 1990 IPO Date |
Hologic, Inc. is a pioneering company focused on improving women’s health through early detection and treatment, leveraging advanced diagnostics, medical imaging systems, and surgical products. Founded in 1985 with its headquarters in Marlborough, Massachusetts, Hologic operates across four distinct segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Its commitment to innovation and improving patient outcomes positions Hologic as a leader in the healthcare industry, ensuring it meets the diverse needs of healthcare providers and patients alike.